1 1

FDA BLA 103705, RITUXAN, Genentech, 11/26/1997

FDA BLA 103705, RITUXAN, Genentech, 11/26/1997

$89.00 USD
$89.00 USD
Sale Sold out

Contents: Summary Basis of Approval (SBA) and supporting safety and efficacy data, clinical study research protocols, supplemental data, and any other documentation associated with the original approval of: Rituxan (rituximab), BLA 97-0244, (BLA): 103705 submitted by Genentech, Inc., in 1997.

BLA: 103705
Company: Genentech
Drug Name: RITUXAN
Active Ingredients: RITUXIMAB
Strength: 100MG/10ML (10MG/ML)
Dosage Form/Route: SOLUTION;INTRAVENOUSPrescription
Action Date: 11/26/1997
Marketing Status: Prescription
Submission Classification: ORIG-1
Action Date: None

54 pages
View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome